Based on 29 Wall Street analysts offering 12-month price targets for Booking Holdings in the last 3 months. The average price target is $4,956.29 with a high forecast of $5,550.00 and a low forecast of $3,874.00.
Based on 8 Wall Street analysts offering 12-month price targets for Microstrategy in the last 3 months. The average price target is $220.00 with a high forecast of $290.00 and a low forecast of $173.00
The 7 analysts with 12-month price forecasts for Tanger stock have an average target of $32.25, with a low estimate of $30.00 and a high estimate of $34. The average target represents a decrease of -7.69% from the current stock price of 34.05.
Based on 12 Wall Street analysts offering 12-month price targets for United Airlines Holdings in the last 3 months. The average price target is $72.92 with a high forecast of $100.00 and a low forecast of $60.00. The average price target represents a 13.85% change from the last price of $64.05.
Here's what the street is saying, folks—24 Wall Street wizards have been busy crunching numbers on Fiserv, and here’s the scoop: they peg the average target at $187.39. But hold on, it gets juicier. The most bullish of the bunch are aiming high at $203.00, while the cautious lot are hedging their bets and stating that their most bearish forecast is around $160.00.
Over the past three months, 17 Wall Street analysts have weighed in on Progressive ($PGR), setting a consensus 12-month price target at $263.00. Expectations vary, with the most bullish analyst projecting a high of $309.00, while the most cautious sees the stock dipping to $197.00.
In the last three months, 13 Wall Street analysts have shared their 12-month price targets for BioNTech SE, with expectations ranging from a low of $85 to a high of $171. The consensus, however, lands at an average price target of $107.36, reflecting mixed views on the company's post-COVID diversification efforts and future revenue streams.
McCormick & Co (NYSE: MKC) has a consensus price target of $77.50 based on ratings from 16 analysts. Price predictions range from $94 on the high end, provided by Exane BNP Paribas, to a more conservative $57 on the low end, forecast by JP Morgan as of January 2024.
Thirteen top analysts have weighed in on Aflac’s stock, setting their 12-month price targets. The average forecast sits at $91.77, with estimates ranging from a low of $75 to a high of $109. If the analysts are right, the average target suggests a potential drop of 15.86% from the current stock price of $109.07.
According to 16 Wall Street analysts who’ve weighed in over the past three months, Cintas has a 12-month average price target of $769.00. The projections range from a high of $875.00 to a low of $590.00. With Cintas currently trading at $799.59, that average target suggests a potential downside of -3.83%..